It is a pharma private limited company based in Hyderabad, Telangana, India, established in 1992.
1992 | Hyderabad, Telangana, India | ActiveSreeven Pharma Private Limited, a active private limited company, was established on 08 July 1992 in Hyderabad, Telangana, India. Engaging in drug formulation & development within the trade sector, it holds CIN: U65993TG1992PTC014481. Registered under ROC Roc Hyderabad. it is unlisted. It has an authorized capital of ₹5.00 Cr and a paid-up capital of ₹3.69 Cr.
Formerly known as Richie Investments & Consultants Pvt Ltd. It upholds a compliant status. Its leadership includes Sandeep Gokaraju (Director), Devendrappa Jegashetty (Managing Director). Past directors included Sandeep Gokaraju, Deelip Sidramappa Patil, Suryakanth Patil. It holds ₹6.00 Cr open charges and ₹9.06 Cr settled loans. Its latest AGM occurred on 30 September 2025, with the balance sheet filed on 31 March 2025. It is based at H.No. 11-15-25, Doctors Colony Lb Nagar, Hyderabad, Telangana, 500074.
U65993TG1992PTC014481
014481
08 July 1992
₹5.00 Cr
₹3.69 Cr
Roc Hyderabad
Unlisted
Active
Explore comprehensive insights into Sreeven Pharma Private Limited — covering financial performance, compliance records, Competitor, shareholding patterns, directors, key metrics, and litigation history. Unlock to see detailed insights and stay informed.
Access Report
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
| Sandeep Gokaraju | Director | 15 Jul 2022 | Current |
| Devendrappa Jegashetty | Managing Director | 11 Apr 2003 | Current |
| Name | Designation | Cessation | Status |
|---|---|---|---|
| Pramod Abcsdd | Additional Director | 30 Sep 2022 | Past |
| Pramod Abcsdd | Director | 27 Nov 2013 | Past |
| Pramod Abcsdd | Director | 22 Apr 2024 | Past |
| Pramod Abcsdd | Director | 30 Mar 2013 | Past |
| Pramod Abcsdd | Director | 22 Apr 2024 | Past |
| Pramod Abcsdd | Director | 30 Mar 2013 | Past |
Discover detailed profiles of directors and KMP - Unlock leadership insights today!
Sreeven Pharma Private Limited, for the financial year ended 2023, experienced significant reduction in revenue, with a 98.86% decrease. The company also saw a substantial fall in profitability, with a 20.61% decrease in profit. The company's net worth observed a substantial decline by a decrease of 1143.23%.
| Metrics |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations |
| ||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
Unlock access to Sreeven Pharma's control and ownership data, Corporate Shareholding Patterns, Funding (security allotment) details, Foreign Institutional Investor information, Directors and Key Management Personnel (KMP) Remuneration, Group Structure, Overseas Direct Investment and other pertinent data.
Reveal ownership structures and financial performance - Get instant access now!
₹60,000,000.00
₹90,600,000.00
| Date | Lender | Amount | Status |
|---|---|---|---|
| 19 Aug 2024 | Axis Bank Limited | ₹6.00 Cr | Open |
| 27 Jan 2017 | Syndicate Bank | ₹1.20 Cr | Satisfied |
| 22 Feb 2016 | Canara Bank | ₹4.95 Cr | Satisfied |
| 26 Aug 2011 | Axis Bank Limited | ₹2.21 Cr | Satisfied |
| 31 Oct 2008 | Syndicate Bank | ₹7.00 M | Satisfied |
Explore comprehensive loan charge details -
Unlock and access historical data on people associated with Sreeven Pharma, such as employment history, contributions to the Employees' Provident Fund Organization (EPFO), and related information.
Gain comprehensive insights into the Deals and Valuation data of Sreeven Pharma, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Sreeven Pharma's trajectory.
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
Sreeven Pharma Private Limited last Annual general meeting of members was held on 30 Sep 2025 as per latest MCA records. was recorded as a recent event.
Sreeven Pharma Private Limited has filed its annual Financial statements for the year ended 31 Mar 2025 with Roc Hyderabad. was recorded as a recent event.
Progress on A charge with Axis Bank Limited amounted to Rs. 6.00 Cr with Charge ID 100972431 was registered on 19 Aug 2024. was documented.
The activity A charge registered on 27 Jan 2017 via Charge ID 100083574 with Syndicate Bank was fully satisfied on 10 Oct 2022. was completed.
Progress on A charge registered on 22 Feb 2016 via Charge ID 10627736 with Canara Bank was fully satisfied on 10 Oct 2022. was documented.
Sandeep Gokaraju was appointed as a Director was appointed as a Director on 15 Jul 2022 & has been associated with this company since 3 years 5 months . was recorded as a recent event.
The CIN of Sreeven Pharma Private Limited is U65993TG1992PTC014481.
Sreeven Pharma Private Limited is headquartered at H.No. 11-15-25, Doctors Colony Lb Nagar, Hyderabad, Telangana, 500074.
Sreeven Pharma Private Limited was incorporated on 08 July 1992.
The current directors of Sreeven Pharma Private Limited are
The primary industry of Sreeven Pharma Private Limited is Trade.
Sreeven Pharma Private Limited is unlisted.
The authorized capital of Sreeven Pharma Private Limited is ₹5.00 Cr, and the paid-up capital is ₹3.69 Cr.
The compliance status of Sreeven Pharma Private Limited is Compliant.
Search company & director profiles for free and gain access to critical business data.
Company Details
+91-XXXXXXXXXX